Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Ferrer Internacional
Deal Size : 568.0
Deal Type : Licensing Agreement
Ferrer and Prilenia Partner for Pridopidine Commercialization and Co-Development
Details : Under the licensing agreement, Ferrer will holds the right to develop TV-7820 (pridopidine) an orally administered sigma-1 receptor agonist. It is being evaluated for Huntington’s Disease.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : $90.8 million
April 28, 2025
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Ferrer Internacional
Deal Size : 568.0
Deal Type : Licensing Agreement
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pridopidine is an oral, highly selective S1R agonist which stimulates multiple cellular pathways, including autophagy, which are essential to neuronal function and survival, and may lead to neuroprotective effects.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alpha-1 Antitrypsin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF.
Product Name : Glassia
Product Type : Protein
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : Alpha-1 Antitrypsin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. It is a novel, PEGylated ERT under development for the treatment of Fabry d...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease
Details : Fast Track accelerate the registration process for pridopidine by providing the ability to file a rolling NDA and qualify for priority review, and administered orally acts as a highly selective and potent Sigma-1 Receptor agonist is for HD and ALS.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegunigalsidase alfa (PRX–102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. Protein sub-units are covalently bound via chemical cross-linking using sho...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following the switch to pegunigalsidase alfa there was a decrease in patients with progressing or fast progressing kidney disease, and the majority of patients achieved a stable status post-switch.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment
Details : The trial is investigating Prilenia’s lead candidate, pridopidine, for treatment of Huntington’s Disease. The study reached 25% in May 2021 and enrolled a further 25% in only six weeks, with now over 240 registered early-stage HD patients.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2021
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Sands Capital
Deal Size : $43.0 million
Deal Type : Series B Financing
Prilenia Closes Oversubscribed $43 Million in Series B Financing Round
Details : The proceeds will be used to prepare for potential registration and commercialization of its lead drug candidate, pridopidine, for patients with Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Sands Capital
Deal Size : $43.0 million
Deal Type : Series B Financing